Introduction
Heart failure (HF) is associated with high mortality and morbidity. 1 Current treatment options for HF patients with a reduced ejection fraction (HFrEF) include angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. These treatments have been shown to improve outcomes in patients with HFrEF.
2 -5 Unfortunately, administration of recommended doses of guideline-directed medication is not often achieved. 6, 7 In the general population, hyperkalaemia is common and may negatively impact the administration of adequate dosages of ACEi and ARB. 8 However, knowledge of this association in patients with HF is lacking. Additionally, hyperkalaemia is associated with worse outcomes and potassium levels are therefore closely monitored during uptitration of renin-angiotensin-aldosterone system (RAAS) inhibitors in clinical trials. 9 -12 Both hyperkalaemia as well as the effect of hyperkalaemia on tolerating higher doses of RAAS inhibitors can severely impede outcomes and interfere with their survival benefit. 8, 13 Currently, no data are available on the independent association of potassium levels (or potassium change during treatment) with the achieved dose of ACEi/ARB. Additionally, limited data are available on the interaction between ACEi/ARB and the association between hyperkalaemia and clinical outcome in patients with HFrEF.
14 Therefore, we aimed to assess the association between serum potassium levels and successful uptitration of ACEi/ARB to HF guideline-directed dosages in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort, which was specifically designed to evaluate the effects of uptitration. 15 Furthermore, we assessed the interaction between guideline-directed treatment and hyperkalaemia on outcomes.
Methods

Study cohort
For the present study, data from BIOSTAT-CHF, an international, multicentre, prospective, observational study, were investigated. Patients received ≤50% of target dosages of ACEi/ARB and/or beta-blockers at time of inclusion, and treating physicians anticipated and encouraged an increase of fraction target dose of ACEi/ARB and/or beta-blockers to guideline-directed levels. Patients were included as inpatients or outpatients. Potassium was measured at time of inclusion. The first 3 months after inclusion were considered as an active uptitration period, followed by a stabilization period of 6 months. Detailed description of the rationale, design, and implementation of the BIOSTAT-CHF study has been reported elsewhere. 15 For the current study, only patients with HFrEF (left ventricular ejection fraction <40%) with available potassium levels at baseline were included. Out of 2516 patients from the original BIOSTAT-CHF study cohort, 697 patients with a preserved or unknown ejection fraction were excluded. Of the remaining 1819 patients, serum potassium levels were measured in 1666 patients. Potassium measurements at 9 months were available in 918 patients (Supplementary Figure S1) 
Definitions and study endpoints
Potassium levels were classified according to clinical reference ranges [i.e. hypokalaemia (<3.5 mEq/L), normokalaemia (3.5-5.0 mEq/L), and hyperkalaemia (>5.0 mEq/L)]. 16 Successful uptitration was defined as an increase in beta-blocker and ACEi/ARB dosage if patients obtained over 50% of the target dose at 9 months of follow-up and the administered dose at 9 months was greater than the dose administered at baseline according to the European Society of Cardiology guidelines.
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Patients who died between baseline and 9 months (n = 203) were excluded from this analysis (Supplementary Figure S1) . Patients receiving equal guideline-recommended target doses (i.e. ≥100%) at baseline and 9 months were classified as successfully uptitrated patients. Patients receiving ≤50% of the guideline-recommended dose were labelled as not successfully uptitrated (Supplementary Figure  S2) . In sensitivity analysis, we did not include baseline doses and only tested for administered doses of ACEi/ARB and beta-blockers at 3 months. 18 The primary endpoint for outcome analyses of this study was a combined endpoint of all-cause mortality and HF-related hospitalizations at 2 years. HF-related hospitalizations were determined by the enrolling investigator. Differences in characteristics between patients with and without potassium measurements at 9 months are shown in Supplementary Table S1 .
Statistical analysis
For baseline characteristics, results for continuous variables are presented as means ± standard deviation, medians (interquartile ranges), or numbers with percentages, as appropriate. Baseline characteristics were stratified by serum potassium levels in hypokalaemia (<3.5 mEq/L), normokalaemia (3.5-5.0 mEq/L), and hyperkalaemia (>5.0 mEq/L), respectively. An increase or decrease in potassium between baseline and 9 months was determined as more than a 0.1 mEq/L difference between baseline and 9 months. Intergroup differences between more than two groups were tested using the one-way analysis of variance (ANOVA), Kruskal-Wallis test, or chi-square test, as appropriate. Q-Q plots and histograms were used to visually test all variables for normality. Normality was tested using the Kolmogorov-Smirnov test, when necessary. For further analyses, skewed variables were log-transformed to achieve normal distribution.
Relationship of potassium levels with successful uptitration between baseline and 9 months was studied using logistic regression. In a stepwise manner, this was corrected for clinically relevant confounders of potassium, including age, sex, estimated glomerular filtration rate (eGFR), systolic blood pressure, diabetes mellitus, and ACEi/ARB use at 9 months (in case of beta-blocker uptitration), or beta-blocker use at 9 months (in case of ACEi/ARB uptitration). Additionally, we corrected for uptitration models that best predicted successful uptitration rates in this cohort for beta-blockers and ACEi/ARB. 18 For beta-blockers, these included age, country of inclusion, diastolic blood pressure, heart rate, and signs of pulmonary congestion. For ACEi/ARB these included sex, body mass index, eGFR, alkaline phosphatase, and country of inclusion, as published previously. 18 The association between potassium and outcome is depicted using Kaplan-Meier curves for potassium levels at baseline, potassium levels at 9 months, and changes in potassium levels between baseline and 9 months. Differences in survival were tested using the log-rank test. To investigate the association of potassium with survival in multivariable analyses, Cox regression analyses were performed correcting for clinically relevant variables, including age, sex, eGFR, hypertension, diabetes mellitus, and ACEi/ARB or beta-blocker use at 9 months. Interaction analyses were performed to investigate Values are given as proportions (%), means ± standard deviation, or medians (interquartile range). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; N/A, not applicable; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure. a Extent of peripheral oedema was determined in 1367 patients. b Serum NT-proBNP levels were determined in 736 patients.
the interaction between successful uptitration and its association with outcome of potassium levels (as a continuous variable).
A two-sided P-value of <0.05 was considered statistically significant, and 95% confidence intervals (CIs) were presented for all odds ratios (ORs). For statistical analyses, Stata MP13 statistical software, release 13 (StataCorp LP., College Station, TX, USA) was used.
Results
Baseline characteristics
Out of a total of 1666 patients, 114 patients (6.9%) had potassium levels <3.5 mEq/L, 1418 patients (85.1%) had normal potassium levels (3. Table 1) . Only 34 patients (2%) had potassium levels >5.5 mEq/L. In the overall population, mean age was 67 ± 12 years, and 77% were male. Patients with hyperkalaemia were more often men, had lower heart rates and less signs of pulmonary congestion and peripheral oedema. Estimated GFR was significantly lower in patients with hyperkalaemia and patients with high serum potassium were more often on MRA treatment. A difference in prevalence of hyper-and hypokalaemia across Europe is depicted in Figure 1 . Hyperkalaemia was particularly prevalent in Slovenia (19%), Poland (13%), Serbia (12%), and Greece (11%) ( Figure 1A) . After correction for potential confounders [i.e. renal function, history of diabetes mellitus, history of hypertension, fraction target dose of ACEi/ARB, beta-blockers, and MRA and uptake of diuretics (yes/no) at baseline], rates of hyperkalaemia were highest in Slovenia, followed by Poland, Serbia, and Greece (P < 0.05 for all). The highest rates of hypokalaemia were found in The Netherlands (P < 0.05) ( Figure 1B and Supplementary Table S2 ). Differences in listed characteristics between European countries are displayed in the Supplementary  Table S3 .
During 9-month follow-up, potassium levels increased (0.16 ± 0.66 mEq/L, P < 0.001) and 523 patients (57%) experienced an increase in potassium levels between baseline and 9 months, while 319 patients (35%) had a decrease in potassium. At 9 months, 21 patients (2.3%) had potassium levels <3.5 mEq/L, 786 patients (85.4%) had normal potassium levels (3. Of patients with hypokalaemia at baseline, 53.5% also had available data at 9 months. In case of normokalaemia and hyperkalaemia at baseline, this was 55.6% and 50.7% at 9 months, respectively (Supplementary Table S4 ).
Association of potassium and uptitration of guideline-directed medication
After 9 months, uptitration of ACEi/ARB was successful in 401 patients (24.1%). For beta-blockers, successful uptitration was achieved in 278 patients (16.7%) (Supplementary Figure S2) . Results of logistic regression analyses are shown in Figure 2 and in the Supplementary Figure S3 . Higher serum potassium at baseline was associated with lower odds of successful uptitration at 9 months in univariable analyses (OR 0.77; 95% CI 0.62-0.95; P = 0.016; per increment of 1.0 mEq/L potassium). Also after correcting for clinically relevant confounders (i.e. age, sex, eGFR, systolic blood pressure, diabetes mellitus, and beta-blocker use at 9 months), higher potassium levels at baseline showed a significant association with less successful uptitration (OR 0.80; 95% CI 0.64-0.99; P = 0.043). When correcting for the previously published uptitration model, higher potassium levels at baseline were still associated with lower odds of successful uptitration (OR 0.70; 95% CI 0.51-0.98; P = 0.035). After excluding patients already on ACEi/ARB target dose, potassium remained predictive for successful uptitration when correcting for both the uptitration model (OR 0.52; 95% CI 0.35-0.78; P = 0.002) and model 3 (OR 0.66; 95% CI 0.50-0.87; P = 0.003). Further adjustment by MRA uptake at target dose (yes/no) did not change the association between baseline potassium levels and ACEi/ARB uptitration when correcting for the uptitration model (OR 0.54; 95% CI 0.35-0.81; P = 0.003) as well as for model 3 (OR 0.68; 95% CI 0.51-0.89; P = 0.006).
No interaction on successful uptitration was observed between potassium and renal function (P interaction = 0.988), suggesting that the association between hyperkalaemia and uptitration is similar across the renal function spectrum. In sensitivity analysis, baseline serum potassium was univariably associated with successful uptitration Figure 3 Combined endpoint of all-cause mortality and heart failure hospitalization rates stratified by serum potassium levels in mEq/L at baseline (A) and 9 months (B).
of ACEi/ARB (OR 0.81; 95% CI 0.67-0.98; P = 0.031). However, this was attenuated after multivariable adjustment (P = 0.086). As expected, no association was found between baseline potassium levels and uptitration of beta-blockers. Higher serum potassium levels at 9 months were not associated with successful uptitration of ACEi/ARB or beta-blockers (Supplementary Figure S3) . A potassium increase over 9 months was associated with successful uptitration of ACEi/ARB (OR 1.37; 95% CI 1.09-1.72; P = 0.008), but not of beta-blockers.
Potassium and outcome
Results of survival analyses are presented in Figure 3 , Supplementary Figure S4 , and Table 2 . Overall, 627 patients (37.6%) reached the combined endpoint at 2 years. Hypo-and hyperkalaemia at baseline or potassium analysed on a continuous scale were not associated with worse outcomes (Table 2) . Similarly, a change in potassium levels between baseline and 9 months or potassium levels at 9 months were not significantly related to outcome. When used as a continuous variable, potassium change during 9 months was not associated with outcome (hazard ratio 0.98; 95% CI 0.81-1.19; P = 0.844). Potassium levels at baseline, a change in potassium during uptitration or potassium levels after uptitration, did not attenuate the beneficial effects of successful uptitration of ACEi/ARB or beta-blockers (P interaction > 0.5 for all).
Discussion
This study shows that low and high serum potassium levels are common among patients with HFrEF. Potassium levels >5.0 mEq/L were observed in 8% of HFrEF patients across Europe, being particularly prevalent in Eastern Europe and Greece. Furthermore, higher baseline potassium levels were an independent predictor of unsuccessful uptitration of ACEi/ARB in HFrEF patients. Potassium levels or changes in potassium levels during uptitration were not associated with worse outcomes. 
19,20
Our study shows an overall rate of baseline potassium abnormalities of 6.9% and 8.0% for hypo-and hyperkalaemia, respectively. Our results show differences in prevalence of potassium abnormalities between European countries, even after rigorous multivariable correction, which might reflect differences in health care systems or local practice. 18 Our findings are in line with earlier reports from the Placebo-Controlled Randomized Study of the Selective A 1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial (6% and 9%, respectively) and the Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) trial (6.7% and 3.3%, respectively).
14 Overall, potassium levels increased during uptitration of ACEi/ARB, with 2.3% of patients having hypokalaemia and 12.3% of patients having hyperkalaemia at 9 months. During 9 months of follow-up, a significant increase in potassium was seen in the majority of patients (57.4%) and can be explained by the actively increased doses of ACEi/ARB. However, the study design did not allow for analysis on early changes (e.g. <1 month) after dose adjustments.
In this study, higher potassium levels at baseline were associated with less uptitration of ACEi/ARB. This suggests that HF patients with hyperkalaemia at the start of therapy are at greater risk for lower doses or discontinuation of ACEi/ARB, which impede outcomes. 6, 18 This is consistent with earlier reports from a general patient population where high potassium levels were found to be responsible for a significant proportion of discontinuation or lowering of ACEi/ARB dosage. Here, discontinuation or Table 2 Cox proportional hazard regression model for the analysis of event rates for the combined endpoint (all-cause mortality + heart failure hospitalizations) in heart failure patients stratified by potassium levels at baseline and 9 months, and potassium change Potassium levels (mEq/L) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
<3.5
3.5-5.0 >5. 0  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . lowering of ACEi/ARB dosages were associated with more adverse outcomes. 8 Also in previous results from the BIOSTAT-CHF study, sub-optimal dosages of ACEi/ARB were associated with worse outcomes in HF patients. 18 This suggests that lower dosages and/or discontinuation of ACEi/ARB due to high potassium levels severely impede outcomes.
Hypokalaemia at baseline or at 9 months was not associated with worse outcomes. This is in line with earlier reports from the COACH, PROTECT and Efficacy of Vasopressin Antagonism in HF Outcome Study of Tolvaptan (EVEREST) trials, where potassium did not show an independent association with outcome.
14,21
Nevertheless, reports on the association of potassium with outcome are mixed. Previous results of post-hoc analyses performed in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial showed that hypokalaemia (<4.0 mEq/L) is associated with adverse outcomes and amplified the beneficial effect of eplerenone. 22, 23 Additionally, a propensity matched study from Ahmed et al. 22 showed that hypokalaemia is associated with more adverse outcomes. In another sub-analysis of the Digitalis Investigation Group trial, Bowling et al. 24 showed that this was also true for HF patients with chronic kidney disease and that potassium also predicts a combined endpoint of all-cause mortality and HF rehospitalization. However, it has been suggested that the association of hypokalaemia with adverse outcomes reflect . (RALES) showed that hyperkalaemia was associated with higher mortality rates, but did not interfere with the beneficial effects of spironolactone. 9 The EMPHASIS-HF trial showed that the favourable effects of eplerenone on outcome did not differ for hyperkalaemic compared to normokalaemic patients. 25 Additionally, a sub-analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) trial showed that potassium levels also did not interfere with the beneficial effects of candesartan. 27 Our findings confirm results of the post-hoc analysis of the CHARM trial, but also suggest that potassium levels do not interfere with the beneficial effects of ACEi/ARB uptitration. Previously, Lund et al. 28, 29 discussed the association between ACEi/ARB use and renal function, indicating that even in HF patients with severe renal insufficiency, administering ACEi/ARB improves outcome. Nevertheless, it should be noted that potassium levels as well as increases in potassium levels during uptitration took place within the relative 'normal' range of potassium levels of 3.0 mEq/L and 5.5 mEq/L. Additionally, our study shows for the first time that potassium increases during ACEi/ARB uptitration do not interfere with the beneficial effects of these lifesaving therapies.
Study limitations
This is a post-hoc analysis, which comes with the usual limitations of selection bias. Potassium levels were only measured twice, at baseline and at 9 months of follow-up. A non-repetitive measurement could falsely positively diagnose a HF patient with hyperkalaemia. Repeated measurements could correct for this deviation, but were not available. Unfortunately, potassium levels were not monitored after the first 3 months of active uptitration. This would provide additional data on potassium fluctuations over time. Additionally, patients with no potassium measurement at 9 months could have died, suggesting caution in interpreting data on potassium and outcome at 9 months. Furthermore, we did not have any information about potassium supplementation as well as on diuretic dosages, which might interfere with potassium levels.
Conclusion
Potassium abnormalities are prevalent among HF patients. Higher potassium levels are associated with lower rates of successful ACEi/ARB uptitration. Potassium abnormalities are not related to adverse outcomes and do not attenuate the beneficial effects of successful ACEi/ARB uptitration.
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